136 related articles for article (PubMed ID: 3849980)
1. Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor.
Hoon DS; Ramshaw IA
Cancer Immunol Immunother; 1985; 20(2):175-8. PubMed ID: 3849980
[TBL] [Abstract][Full Text] [Related]
2. Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of the murine mammary tumor.
Nakajima H; Abe S; Masuko Y; Tsubouchi J; Yamazaki M; Mizuno D
Gan; 1981 Oct; 72(5):723-31. PubMed ID: 7327373
[TBL] [Abstract][Full Text] [Related]
3. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
5. Systemic adoptive transfer of immunity and low-dose irradiation eradicate metastases of 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL; Christensen ND; Welsh P
Int J Cancer; 1985 Aug; 36(2):217-24. PubMed ID: 3160672
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.
Archer TP; Bretscher P; Ziola B
Clin Exp Metastasis; 1990; 8(6):519-32. PubMed ID: 2225567
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
Fisher B; Gebhardt M
Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the expression of adoptive tumor rejection immunity by recipient cyclophosphamide-sensitive cells.
Boyer CM; Kreider JW; Bartlett GL
Cancer Res; 1982 Jun; 42(6):2211-5. PubMed ID: 7042079
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
11. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.
Barlozzari T; Leonhardt J; Wiltrout RH; Herberman RB; Reynolds CW
J Immunol; 1985 Apr; 134(4):2783-9. PubMed ID: 3871818
[TBL] [Abstract][Full Text] [Related]
12. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of T cells involved in the expression of delayed hypersensitivity and tumor rejection immunity to 13762A rat mammary adenocarcinoma.
Kreider JW; Howell LE; Bartlett GL
Cell Immunol; 1985 Jun; 93(1):26-37. PubMed ID: 3922632
[TBL] [Abstract][Full Text] [Related]
14. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid.
Youn JK; Lacour F; Hue G
Cancer Res; 1982 Nov; 42(11):4706-11. PubMed ID: 7127305
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Mokyr MB; Colvin M; Dray S
Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
[TBL] [Abstract][Full Text] [Related]
17. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
18. Single-dose cyclophosphamide for the prevention of bladder tumor implantation in F344 rats: site of drug activity.
See WA; Crist SA; Williams RD
Cancer Res; 1991 Mar; 51(5):1378-83. PubMed ID: 1997176
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.
Kadhim S; Penney C; Lagraoui M; Heibein J; Attardo G; Zacharie B; Connolly T; Gagnon L
Int J Immunopharmacol; 2000 Sep; 22(9):659-71. PubMed ID: 10884587
[TBL] [Abstract][Full Text] [Related]
20. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
